Leo O'Connor

A handful of firms have announced they are developing at-home combo kits that can detect and differentiate COVID-19, flu A, and B on current testing platforms.

The firm expects to soon obtain CE marking for the QuickMIC system to measure the susceptibility of Gram-negative bacteria to 12 antibiotics in clinical settings.

As the firm continues to develop assays to run on a current batch-based MDx system, it seeks to develop a more flexible, random-access testing platform.

The firm is sketching plans to drive greater revenue growth by improving its laboratory processes and developing broader NGS panels.

The commission expects to launch an alliance to implement recommendations from a Lancet report about transforming access to diagnostics in LMICs.

The CardioGenomic Testing Alliance aims to increase the utilization of NGS panels for numerous cardiac conditions including arrhythmias and cardiomyopathies.

The researchers used mass spec and data analytics to develop lipid profiles that predicted diabetes and cardiovascular disease risk in the distant future.

A consortium led by Boston Cell Standards aims to integrate analytic reference standards and calibration tools into routine immunohistochemistry testing.

The firm said the technology for a blood test it is developing for sepsis could be used to assess the risk of COVID-19 patients having a severe or mild illness.

Hopkins researchers are validating a nanosensor platform to detect SARS-CoV-2 and other viruses that consists of a single-use chip and handheld spectrometer.